Raloxifene and Bazedoxifene Could Be Promising Candidates for Preventing the COVID-19 Related Cytokine Storm, ARDS and Mortality
Raloxifene and Bazedoxifene Could Be Promising Candidates for Preventing the COVID-19 Related Cytokine Storm, ARDS and Mortality
复制标题
DOI：
10.21873/invivo.12135
复制
发表时间：
2020-09-01
期刊：
影响因子：
2.3
通讯作者：
BrAbek, Jan
中科院分区：
文献类型：
--
作者：
Smetana Jr, Karel;Rosel, Daniel;BrAbek, Jan
FDA批准的药物雷洛昔芬和巴多昔芬可能是预防严重COVID-19患者死亡的最佳候选药物之一。雷洛昔芬和巴多昔芬在治疗剂量下抑制IL-6信号传导，表明它们有可能预防严重COVID-19患者的细胞因子风暴、ARDS和死亡率，正如阻断IL-6信号传导的人源化抗体所显示的那样。此外，雷洛昔芬和巴多昔芬是具有强抗病毒活性的选择性雌激素受体调节剂。
The FDA-approved drugs raloxifene and bazedoxifene could be among the best candidates to prevent mortality in severe COVID-19 patients. Raloxifene and bazedoxifene inhibit IL-6 signaling at therapeutic doses, suggesting they have the potential to prevent the cytokine storm, ARDS and mortality in severe COVID-19 patients, as is being shown with humanized antibodies blocking IL-6 signaling. In addition, raloxifene and bazedoxifene are selective estrogen receptor modulators with strong antiviral activity.